|Articles|July 1, 2001

Pharmaceutical Executive-07-01-2001
Volume 0
Issue 0

Generic Threat

Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.

Articles in this issue

about 25 years ago

Article

Pharmacies: OTC Price Wars

about 25 years ago

Article

One Disease at a Time

about 25 years ago

Article

Overview of the Industry: A World of Opportunities

about 25 years ago

Article

The Power Shift

about 25 years ago

Article

A Giant Stumbles

about 25 years ago

Article

Overruled: No More Dual Pricing

about 25 years ago

Article

Submerged

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

September 18th, 2026

Pharmaceutical Executive Daily: FDA Approves Fayuvi

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

September 18th, 2026

M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.

September 18th, 2026

FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A

FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.

September 18th, 2026

Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham

Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.

September 18th, 2026

Addressing MFN Innovation Concerns

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.

September 18th, 2026

RWD's Impact on Clinical Trial Recruitment Costs

Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.

September 18th, 2026

Your Questions Answered: AI Drug Discovery, Portfolio Simplification, and a 30-Year First

Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.

September 18th, 2026

The Shift Towards a Patient-Centric Culture in Pharma

Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.

Generic Threat

Articles in this issue

Related to this article

Trending on PharmExec

M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz

Pharmaceutical Executive Daily: FDA Approves Fayuvi

The Battle to Own the GLP-1 Patient Journey

FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A

Your Questions Answered: AI Drug Discovery, Portfolio Simplification, and a 30-Year First